Current anti-epileptic drugs (AEDs) form the first-line treatment option for patients with trigeminal neuralgia (TN), however, diminishing efficacy and increasing side effects can leave symptoms inadequately controlled. Greater understanding and new, improved treatment options are required to reduced impact on patients’ quality of life.
Why this matters
TN is an orofacial condition defined by excruciating electric shock-like pain, abrupt in onset and termination with episodes sometimes triggered by innocuous stimuli.
The condition can greatly impact quality of life with current first-line therapy often inadequate in effectively controlling symptoms.